Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Share :
Published: 13 Oct 2026
Views: 47
Rating:
Save
Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA

Dr Alex Spira speaks to ecancer about a global phase I study that evaluates three doses of iza-bren (izalontamab brenitecan), an EGFR and HER3 bispecific antibody drug conjugate, in patients with previously treated EGFR-mutated metastatic NSCLC.

Among 80 patients who had progressed on third-generation EGFR inhibitors, iza-bren achieved an overall response rate of 28.8% and median progression-free survival of 5.4 months.

At the 2.5 mg/kg dose, the overall response rate was 33.3% and median progression-free survival was 6.9 months.

Dr Spira says that grade 3 or higher treatment-related adverse events occurred in 47.5% of patients, most commonly anaemia and neutropenia.

He highlights that the findings support 2.5 mg/kg as the recommended phase III dose, with primary G-CSF prophylaxis helping to manage haematological toxicity.

Related Videos

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC ( Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
28 Sep 2026

Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC

Dr Chul Kim - Georgetown Cancer Institute, Washington, USA
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC ( Dr Chul Kim - Georgetown Cancer Institute, Washington, USA )
28 Sep 2026

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )
18 Sep 2026

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
31 May 2026

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )
11 May 2026

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )
23 Apr 2026

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer ( Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA )
15 Apr 2026

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer

Dr Eva-Lotte Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer ( Dr Eva-Lotte Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany )
15 Apr 2026

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer

Dr Saumil Gandhi - University of Texas MD Anderson Cancer Center, Houston, USA
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer ( Dr Saumil Gandhi - University of Texas MD Anderson Cancer Center, Houston, USA )
15 Apr 2026